Emiliem, Inc. - Molecularly Targeted Oncology Therapeutics, Multi-Kinase Inhibitor

Corporate

Management

President & Chief Executive Officer, Director - Dale E. Johnson, Pharm.D., Ph.D

Dale Johnson has over 25 years of experience in biotechnology and pharmaceutical research and development activities where he has led and managed groups ranging from small units in start-up companies to multi-national units in large corporations. Most recently, he served as Vice President, Drug Assessment & Development at Chiron Corporation and previously as Vice President, Preclinical Development. He also has held executive positions in large global pharmaceutical and start-up biotechnology companies.

Chief Scientific Officer, Director - Sucha Sudarsanam, M.S.

Sucha Sudarsanam, over the last 17 years, has become internationally recognized as a leader in the bioinformatics field. Most recently, he was head of R&D Informatics at Chiron Corp. where he led the creation of an informatics infrastructure for translational medicine, integrating discovery and clinical systems. Previously, he led the bioinformatics department at Sugen and was Global Director of Bioinformatics at Pharmacia where he was noted for seminal work on the human kinome.

VP, Intellectual Property, Secretary - Edwin P. Ching, J.D., Ph.D.

Edwin Ching has more than 18 years of legal experience working with biotechnology companies and a leading law firm. Most recently, he was Patent Counsel for Gangagen Inc and VP, Intellectual Property at Eos Biotechnology. He has extensive experience in patent filings and prosecution both in US and overseas.

Chief Business Officer, Director - James Burden, J.D.

Jim Burden has forty years of experience in corporate finance, law practice, and business operations. He has co-founded, financed, and operated a number of companies, many of which are in the bioscience area. He is President and majority owner of Dorset Capital, LLC, a company that facilitates the formation and financing of companies both in the U.S. and in the United Kingdom.

Chief Financial Officer - Henry C. Settle, Jr., M.B.A., C.P.A.

Hank Settle has been a principal and a financial consultant with life sciences and technology companies. At Ernst & Young, he served as a partner in the firm’s life sciences practice in Palo Alto where he led teams serving approximately 40 emerging companies in the biotechnology and medical device fields, many of which were public companies. Most recently, he was Chief Financial Officer of KineMed, Inc.

VP, Chemical Sciences and Pharmaceutical Development – Donna L Romero, Ph.D.

Donna Romero has over 20 years of experience in leading and supervising medicinal chemistry teams and multiple scientific programs across disciplines and therapeutic areas in the Upjohn, Pharmacia, and Pfizer pharmaceutical companies. She was the inventor of the non-nucleoside reverse transcriptase inhibitor Rescriptor® marketed for the treatment of HIV. Most recently she was Senior Director, Medicinal Chemistry at Pfizer, St. Louis.

Director, Project Management – Diane Charron Beuving, M.S.

Diane Beuving has over 20 years experience in project management and leading exploratory and full development teams in the Upjohn, Pharmacia, and Pfizer pharmaceutical companies. Additionally, she has several years experience in international regulatory affairs and business development. Most recently she was Director, Global Project Management for Pfizer, Michigan Laboratories.

Scientific Advisory Board

Bahija Jallal, Ph.D. Bahija Jallal is Vice President, Translational Sciences and Oncology at MedImmune, Inc. where she leads the preclinical and clinical biomarker functions and also directs the toxicology/pathology, clinical assays and in vivo/ex vivo biology efforts.

Manoj C. Desai, Ph.D. Manoj Desai is Vice President, Medicinal Chemistry at Gilead Sciences, whose areas of leadership have included medicinal chemistry, chemical informatics, computational chemistry, protein X-ray crystallography, combinatorial chemistry, analytical chemistry and bioorganic chemistry.

Sean Ekins, Ph.D., D.Sc. Sean Ekins is Senior Vice President of Computational Biology at Arnold Consultancy and Technology LLC, and has expertise in the areas of computational drug discovery, systems biology applied to pathway and biomarker discovery, and in vitro and computational ADME/Tox.



	HOME \| ABOUT \| CORPORATE \| BUSINESS MODEL\| PIPELINE \| PRESS \| NEWS \| CONTACT

	Corporate Management President & Chief Executive Officer, Director - Dale E. Johnson, Pharm.D., Ph.D Dale Johnson has over 25 years of experience in biotechnology and pharmaceutical research and development activities where he has led and managed groups ranging from small units in start-up companies to multi-national units in large corporations. Most recently, he served as Vice President, Drug Assessment & Development at Chiron Corporation and previously as Vice President, Preclinical Development. He also has held executive positions in large global pharmaceutical and start-up biotechnology companies. Chief Scientific Officer, Director - Sucha Sudarsanam, M.S. Sucha Sudarsanam, over the last 17 years, has become internationally recognized as a leader in the bioinformatics field. Most recently, he was head of R&D Informatics at Chiron Corp. where he led the creation of an informatics infrastructure for translational medicine, integrating discovery and clinical systems. Previously, he led the bioinformatics department at Sugen and was Global Director of Bioinformatics at Pharmacia where he was noted for seminal work on the human kinome. VP, Intellectual Property, Secretary - Edwin P. Ching, J.D., Ph.D. Edwin Ching has more than 18 years of legal experience working with biotechnology companies and a leading law firm. Most recently, he was Patent Counsel for Gangagen Inc and VP, Intellectual Property at Eos Biotechnology. He has extensive experience in patent filings and prosecution both in US and overseas. Chief Business Officer, Director - James Burden, J.D. Jim Burden has forty years of experience in corporate finance, law practice, and business operations. He has co-founded, financed, and operated a number of companies, many of which are in the bioscience area. He is President and majority owner of Dorset Capital, LLC, a company that facilitates the formation and financing of companies both in the U.S. and in the United Kingdom. Chief Financial Officer - Henry C. Settle, Jr., M.B.A., C.P.A. Hank Settle has been a principal and a financial consultant with life sciences and technology companies. At Ernst & Young, he served as a partner in the firm’s life sciences practice in Palo Alto where he led teams serving approximately 40 emerging companies in the biotechnology and medical device fields, many of which were public companies. Most recently, he was Chief Financial Officer of KineMed, Inc. VP, Chemical Sciences and Pharmaceutical Development – Donna L Romero, Ph.D. Donna Romero has over 20 years of experience in leading and supervising medicinal chemistry teams and multiple scientific programs across disciplines and therapeutic areas in the Upjohn, Pharmacia, and Pfizer pharmaceutical companies. She was the inventor of the non-nucleoside reverse transcriptase inhibitor Rescriptor® marketed for the treatment of HIV. Most recently she was Senior Director, Medicinal Chemistry at Pfizer, St. Louis. Director, Project Management – Diane Charron Beuving, M.S. Diane Beuving has over 20 years experience in project management and leading exploratory and full development teams in the Upjohn, Pharmacia, and Pfizer pharmaceutical companies. Additionally, she has several years experience in international regulatory affairs and business development. Most recently she was Director, Global Project Management for Pfizer, Michigan Laboratories. Scientific Advisory Board Bahija Jallal, Ph.D. Bahija Jallal is Vice President, Translational Sciences and Oncology at MedImmune, Inc. where she leads the preclinical and clinical biomarker functions and also directs the toxicology/pathology, clinical assays and in vivo/ex vivo biology efforts. Manoj C. Desai, Ph.D. Manoj Desai is Vice President, Medicinal Chemistry at Gilead Sciences, whose areas of leadership have included medicinal chemistry, chemical informatics, computational chemistry, protein X-ray crystallography, combinatorial chemistry, analytical chemistry and bioorganic chemistry. Sean Ekins, Ph.D., D.Sc. Sean Ekins is Senior Vice President of Computational Biology at Arnold Consultancy and Technology LLC, and has expertise in the areas of computational drug discovery, systems biology applied to pathway and biomarker discovery, and in vitro and computational ADME/Tox.